GT Biopharma Statistics
Share Statistics
GT Biopharma has 2.23M shares outstanding. The number of shares has increased by -94.5% in one year.
| Shares Outstanding | 2.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.96M |
| Failed to Deliver (FTD) Shares | 572 |
| FTD / Avg. Volume | 2.56% |
Short Selling Information
The latest short interest is 17.73K, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 17.73K |
| Short % of Shares Out | 0.79% |
| Short % of Float | 0.9% |
| Short Ratio (days to cover) | 0.71 |
Valuation Ratios
The PE ratio is -1.36 and the forward PE ratio is -0.28.
| PE Ratio | -1.36 |
| Forward PE | -0.28 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 1.38 |
| P/FCF Ratio | -1.16 |
| PEG Ratio | n/a |
Enterprise Valuation
GT Biopharma Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.12, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.12 |
| Quick Ratio | 2.12 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.77 |
| Cash Flow / Debt | -152.62 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.02% and return on capital (ROIC) is -180.2%.
| Return on Equity (ROE) | -1.02% |
| Return on Assets (ROA) | -0.54% |
| Return on Capital (ROIC) | -180.2% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -3.80M |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -62.03% in the last 52 weeks. The beta is 0.57, so GT Biopharma 's price volatility has been higher than the market average.
| Beta | 0.57 |
| 52-Week Price Change | -62.03% |
| 50-Day Moving Average | 2.75 |
| 200-Day Moving Average | 3.06 |
| Relative Strength Index (RSI) | 47.61 |
| Average Volume (20 Days) | 22.34K |
Income Statement
In the last 12 months, GT Biopharma had revenue of $0 and earned -$7.60M in profits. Earnings per share was $-5.64.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -13.58M |
| Net Income | -7.60M |
| EBITDA | 5.98M |
| EBIT | - |
| Earnings Per Share (EPS) | -5.64 |
Balance Sheet
The company has $1.08M in cash and $58.00K in debt, giving a net cash position of $1.02M.
| Cash & Cash Equivalents | 1.08M |
| Total Debt | 58.00K |
| Net Cash | 1.02M |
| Retained Earnings | -682.07M |
| Total Assets | 6.76M |
| Working Capital | 2.10M |
Cash Flow
In the last 12 months, operating cash flow was -$8.85M and capital expenditures $0, giving a free cash flow of -$8.85M.
| Operating Cash Flow | -8.85M |
| Capital Expenditures | 0 |
| Free Cash Flow | -8.85M |
| FCF Per Share | -6.57 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
GTBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -200.71% |
| FCF Yield | -141.05% |
Analyst Forecast
The average price target for GTBP is $11, which is 291.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 291.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Feb 5, 2024. It was a backward split with a ratio of 1:30.
| Last Split Date | Feb 5, 2024 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -149.83 |
| Piotroski F-Score | 0 |